Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies

被引：2

作者：

Wang, Kang ^{[1
]}

Wang, Yun ^{[2
]}

Yin, Kai ^{[3
]}

机构：

[1] Jiangsu Univ, Affiliated Hosp, Dept Gen Surg, Jiefang Rd 438, Zhenjiang 212000, Jiangsu, Peoples R China

[2] First Peoples Hosp Changzhou, Dept Dermatol, Juqian St, Changzhou 213003, Jiangsu, Peoples R China

[3] Jiangsu Univ, Affiliated Hosp, Inst Digest Dis, Dept Gen Surg, Jiefang Rd 438, Zhenjiang 212000, Jiangsu, Peoples R China

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2024年 / 150卷 / 05期

基金：

中国国家自然科学基金;

关键词：

MDSC; Colitis-associated colorectal cancer; CRC; Targeting strategies; PHASE-II TRIAL; SUPPRESSOR-CELLS; OPEN-LABEL; MYELOID CELLS; CHEMOTHERAPY; PROMOTES; DIFFERENTIATION; MULTICENTER; BEVACIZUMAB; EFFICACY;

D O I：

10.1007/s00432-024-05755-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colitis-associated colorectal cancer has been a hot topic in public health issues worldwide. Numerous studies have demonstrated the significance of myeloid-derived suppressor cells (MDSCs) in the progression of this ailment, but the specific mechanism of their role in the transformation of inflammation to cancer is unclear, and potential therapies targeting MDSC are also unclear. This paper outlines the possible involvement of MDSC to the development of colitis-associated colorectal cancer. It also explores the immune and other relevant roles played by MDSC, and collates relevant targeted therapies against MDSC. In addition, current targeted therapies for colorectal cancer are analyzed and summarized.

引用

页数：19

共 50 条

[31] Piperlongumine Alleviates Mouse Colitis and Colitis-Associated Colorectal Cancer
Huang, Jia-Rong
Wang, Sheng-Te
Wei, Meng-Ning
Liu, Kun
Fu, Jing-Wen
Xing, Zi-Hao
Shi, Zhi
FRONTIERS IN PHARMACOLOGY, 2020, 11
[32] Innate immune mechanisms of colitis and colitis-associated colorectal cancer
Saleh, Maya
Trinchieri, Giorgio
NATURE REVIEWS IMMUNOLOGY, 2011, 11 (01) : 9 - 20
[33] Innate immune mechanisms of colitis and colitis-associated colorectal cancer
Maya Saleh
Giorgio Trinchieri
Nature Reviews Immunology, 2011, 11 : 9 - 20
[34] Therapeutic potential of Pien Tze Huang in colitis-associated colorectal cancer: mechanistic insights from a mouse model
Liu, Liya
Chen, Youqin
Liu, Sijia
Zhang, Xinran
Cao, Liujing
Wu, Yulun
Han, Yuying
Lin, Guosheng
Wei, Lihui
Fang, Yi
Sferra, Thomas J.
Jafri, Anjum
Liu, Huixin
Li, Li
Shen, Aling
CANCER CELL INTERNATIONAL, 2024, 24 (01)
[35] Citrullination of miRNA regulators by PADs: A potential mechanism for the promotion of colitis and colitis-associated colorectal cancer
Witalison, Erin E.
Cui, Xiangli
Causey, Corey P.
Thompson, Paul R.
Hofseth, Lorne J.
CANCER RESEARCH, 2015, 75
[36] MicroRNA-449a is a potential predictor of colitis-associated colorectal cancer progression
Feng, Yun
Dong, Yu-Wei
Song, Yun-Na
Xiao, Jun-Hua
Guo, Xing-Ya
Jiang, Wei-Liang
Lu, Lun-Gen
ONCOLOGY REPORTS, 2018, 40 (03) : 1684 - 1694
[37] The role of FKBP51 in the prognosis of ulcerative colitis-associated colorectal cancer
Xia, Zhixiu
Zhang, Guohua
Wang, Changliang
Feng, Yong
ADVANCES IN MEDICAL SCIENCES, 2021, 66 (01): : 89 - 97
[38] The Protective Role of Bacteroides fragilis in Murine Model of Colitis-Associated Colorectal Cancer
Lee, Yun Kyung
Mehrabian, Parpi
Boyajian, Silva
Wu, Wei-Li
Selicha, Jane
Vonderfecht, Steven
Mazmanian, Sarkis K.
MSPHERE, 2018, 3 (06)
[39] Protective effects of palbociclib on colitis-associated colorectal cancer
Yang, Li
Gao, Jiani
Zhang, Yuqin
Perez, Eduardo A.
Wu, Yuchen
Guo, Tianan
Li, Cong
Wang, Hao
Xu, Ye
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (06) : 2436 - 2447
[40] PPARδ agonist enhances colitis-associated colorectal cancer
Zhou, Danya
Jin, Jianhua
Liu, Qian
Shi, Juanjuan
Hou, Yongzhong
EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 842 : 248 - 254

← 1 2 3 4 5 →